Cancer Supportive Care Market by Therapeutic Area, Distribution Channel, and Geography - Forecast and Analysis 2023-2027

Published: Jan 2023 Pages: 175 SKU: IRTNTR41301

Cancer Supportive Care Market Forecast 2023-2027

The cancer supportive care market is estimated to grow by USD 6.56 billion at a CAGR of 4.62% between 2022 and 2027. The growing prevalence of cancer cases worldwide is increasing the demand for effective treatments and supportive care options. Many side effects associated with cancer treatment, such as nausea, pain, and fatigue, create a need for supportive care products to improve patients' quality of life. The untapped potential in developing countries presents opportunities for market expansion, as these regions seek to improve access to cancer care and treatment options. It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the Market During the Forecast Period?

View the Bestselling Market Report sample Instantly

Market Segmentation

This market report extensively covers market segmentation by therapeutic area (chemotherapy-induced anemia, chemotherapy-induced neutropenia, cancer pain, CINV, and others), distribution channel (hospitals pharmacies, drug stores and retail pharmacies, and online providers), and geography (North America, Europe, Asia, and Rest Of World (ROW)). 

By Therapeutic Area

The market share growth of the chemotherapy-induced anemia segment will be significant during the forecast period. Anemia is a condition that develops when the blood lacks the required amount of healthy red blood cells or hemoglobin. Anemia is one of the most common types of side effects faced by individuals undergoing treatment. Almost all individuals going through chemotherapy suffer mild anemia, and more than three-fourths of them develop more severe problems. As these cases are rising in developing countries as well, the higher adoption rate of chemotherapy will increase the demand for drugs indicated for chemotherapy-induced anemia, thereby driving market growth.

Get a glance at the market contribution of various segments Request a PDF Sample

The chemotherapy-induced anemia segment was valued at USD 6.13 billion in 2017. Cancer or chemotherapeutic drugs can cause anemia in an individual. Cancer suppresses erythropoiesis, leading to anemia. Chemotherapy targets fast-dividing cells as well as healthy cells in the body. The cells in the bone marrow are highly sensitive to chemotherapy, resulting in the decreased production of red blood cells in the body. As the destruction of bone marrow is certain post-chemotherapy, the cases of anemia will rise in developed countries as well, thereby driving market growth.

By Region

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America holds the largest share of the market owing to the huge investments made in the oncology sector in the US. The US dominates the regional market and acts as the major revenue generator, followed by Canada. Huge investments in the pharmaceutical industry, specifically the oncology sector, and the presence of pharmaceutical giants in the region are some of the major factors backing the dominance of the US in the region as well as globally. This is one of the most common chronic diseases in the US. Also, in every 100,000 population, 436 new cancer cases were reported, and about 156 died of cancer in the country in the same year. Thus, with the growing incidences of cancer, companies will invest in extensive research to develop effective drugs for the treatment of several cancers. As these drugs are associated with several side effects, the demand is expected to increase in the region during the forecast period.

Market Dynamics and Customer Landscape

The market encompasses a range of treatments and medications aimed at improving the quality of life for cancer patients undergoing chemotherapy and other treatments. These include Granulocyte Colony-Stimulating Factors (GCSFs) to boost white blood cell production, Antiemetics to manage nausea and vomiting, and supportive care drugs to address various side effects like anemia and hair loss. Organizations like the National Cancer Institute and the American Cancer Society play key roles in advancing research and promoting access to these treatments. As the cancer prevalence increases, particularly among the geriatric population, there's a growing focus on supportive care to enhance treatment outcomes and mitigate adverse effects. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The growing prevalence of cancer cases is notably driving market growth. This is increasingly becoming a significant health concern worldwide, leading to higher mortality rates. Genetic mutations, environmental factors like tobacco smoking and pollution, and changing dietary habits are major contributors to the development. Understanding these factors is crucial for developing effective prevention and treatment strategies. Additionally, managing these involves considerations such as new patient E&M visits, current patient E&M visits, the use of biosimilars and generic medications, and the use of ESA (erythropoiesis-stimulating agents) when appropriate. The growing prevalence of these factors has directly contributed to the rising incidence, making it the second leading cause of death globally. It's crucial to register cancer diagnoses, treatment rates, and mortality to understand trends in a country. Medical researchers require current cancer-related data to monitor trends and investigate potential causes. Healthcare providers need this data to make informed decisions about equipment and medication procurement for treatment and to develop awareness and prevention programs. The increasing incidence and prevalence of cancer are expected to drive demand, leading to market growth in this area.

Significant Market Trends

The advent of biosimilars in cancer-associated treatment is the primary trend in the market. The growing demand for quality care has led to the increased use of erythropoietin drugs for the treatment of chemotherapy-induced anaemia. The majority of countries are under pressure to address this demand without increasing healthcare expenditure. Biosimilars will likely play a prominent role in this scenario, as, unlike generic drugs, they have the same active pharmaceutical ingredients as their originator biological compounds. Biosimilars are less expensive than biologics, thereby increasing accessibility. The patent expiry of biologics has led to the emergence of their biosimilars.

Epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar version of Epoetin alfa. JCR Pharmaceuticals is also developing JR-013-sc Erythropoietin (which is under the Phase I stage of development) and JR-131 Darbopoietin (which is under the preclinical stage of development); both are of recombinant DNA origin. In addition, low-cost biosimilars are expected to affect the prices of branded drugs, thereby increasing the accessibility of drugs.

Major Market Challenge

The increasing preference for targeted therapies over chemotherapy drugs will hinder the growth prospects of the market. As there is an increased need to target specific molecules that are responsible for the growth of cancer, companies are focusing on the development of targeted therapies, which have higher specificity than traditional chemotherapy drugs. Also, as chemotherapy drugs are associated with several side effects, researchers are conducting extensive R&D activities to better understand the disease's etiology and develop novel treatments.

companies are investing huge amounts to obtain approval for their cancer drugs. For instance, Boston-based Blueprint Medicines received clearance from the US FDA for its genetically targeted cancer therapy, Ayvakit, which is used for the treatment of gastrointestinal stromal tumours. Such market dynamics may hamper the market growth.

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Cancer Supportive Care Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Amgen Inc. - The company offers cancer-supportive care products such as Neulasta and Aranesp. This segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.

The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Helsinn Healthcare SA
  • Heron Therapeutics Inc.
  • Johnson and Johnson
  • Kyowa Kirin Co. Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharma LP
  • RELIEF THERAPEUTICS Holding SA
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Therapeutic Area Outlook 
    • Chemotherapy-induced anemia
    • Chemotherapy-induced neutropenia
    • Cancer pain
    • CINV
    • Others
  • Distribution Channel Outlook 
    • Hospitals pharmacies
    • Drug stores and retail pharmacies
    • Online providers
  • Region Outlook 
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW) 
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

Market Analyst Overview

The market is driven by the rising prevalence of breast cancer, colorectal cancer, lung cancer, and liver cancer, necessitating effective treatments to manage symptoms and side effects. This market encompasses a range of drugs, including erythropoiesis-stimulating agents (ESA) and granulocyte colony-stimulating factors (G-CSFs), designed to address issues like nausea and vomiting control and infection prevention. With a focus on patient-centric care and personalized medicine, new drugs are continuously being developed and tested in clinical trials to improve outcomes. The market is also influenced by regulatory frameworks and reimbursement policies, particularly from organizations like the Centers for Medicare and Medicaid Innovation (CMMI) and the World Health Organization (WHO). Increasing convenience through channels like e-commerce and online pharmacies is also shaping the market landscape.

The market is vital in addressing the complex needs of cancer patients, offering bisphosphonates for managing bone complications and G-CSFs (granulocyte colony-stimulating factors) to boost white blood cell production post-chemotherapy. These drugs are crucial in managing symptoms and side effects, especially for patients with metastatic colorectal cancer and prostate cancer. The market is supported by various distribution channels, including hospital pharmacies, drug stores & retail pharmacies, and online pharmacies, ensuring accessibility to these essential medications. The market plays a crucial role in addressing the diverse needs of cancer patients. With a focus on managing symptoms and side effects, it offers a range of drugs and treatments. This market encompasses various aspects, including distribution channels like hospital and Retail pharmacy, as well as Online pharmacy, ensuring easy access to medications. Cell research advancements drive the development of innovative therapies, while the market navigates challenges such as economic recessions. It remains pivotal in supporting patients and improving their quality of life.

 Market Scope

Report Coverage

Details

Page number

175

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 4.62%

Market growth 2023-2027

USD 6.56 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

3.92

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key countries

US, Canada, UK, Germany, and China

Competitive landscape

 Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks

Key companies profiled

Acacia Pharma Group Plc, Amgen Inc., Baxter International Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Johnson and Johnson, Kyowa Kirin Co. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, RELIEF THERAPEUTICS Holding SA, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapeutic Area
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global cancer supportive care market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global cancer supportive care market 2017 - 2021 ($ million)
    • 4.2 Therapeutic area Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Therapeutic area Segment 2017 - 2021 ($ million)
    • 4.3 Distribution channel Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Therapeutic Area

    • 6.1 Market segments
      • Exhibit 30: Chart on Therapeutic Area - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Therapeutic Area - Market share 2022-2027 (%)
    • 6.2 Comparison by Therapeutic Area
      • Exhibit 32: Chart on Comparison by Therapeutic Area
      • Exhibit 33: Data Table on Comparison by Therapeutic Area
    • 6.3 Chemotherapy-induced anemia - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Chemotherapy-induced anemia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Chemotherapy-induced anemia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Chemotherapy-induced anemia - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Chemotherapy-induced anemia - Year-over-year growth 2022-2027 (%)
    • 6.4 Chemotherapy-induced neutropenia - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Chemotherapy-induced neutropenia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Chemotherapy-induced neutropenia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Chemotherapy-induced neutropenia - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Chemotherapy-induced neutropenia - Year-over-year growth 2022-2027 (%)
    • 6.5 Cancer pain - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Cancer pain - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Cancer pain - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Cancer pain - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Cancer pain - Year-over-year growth 2022-2027 (%)
    • 6.6 CINV - Market size and forecast 2022-2027
      • Exhibit 46: Chart on CINV - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Data Table on CINV - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Chart on CINV - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on CINV - Year-over-year growth 2022-2027 (%)
    • 6.7 Others - Market size and forecast 2022-2027
      • Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.8 Market opportunity by Therapeutic Area
      • Exhibit 54: Market opportunity by Therapeutic Area ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 55: Chart on Distribution Channel - Market share 2022-2027 (%)
      • Exhibit 56: Data Table on Distribution Channel - Market share 2022-2027 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 57: Chart on Comparison by Distribution Channel
      • Exhibit 58: Data Table on Comparison by Distribution Channel
    • 7.3 Hospitals pharmacies - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Hospitals pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on Hospitals pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on Hospitals pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Hospitals pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.4 Drug stores and retail pharmacies - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Drug stores and retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on Drug stores and retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on Drug stores and retail pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2022-2027 (%)
    • 7.5 Online providers - Market size and forecast 2022-2027
      • Exhibit 67: Chart on Online providers - Market size and forecast 2022-2027 ($ million)
      • Exhibit 68: Data Table on Online providers - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Chart on Online providers - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on Online providers - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 71: Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 73: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 75: Chart on Geographic comparison
      • Exhibit 76: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 97: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 101: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 China - Market size and forecast 2022-2027
      • Exhibit 105: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 107: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.11 Canada - Market size and forecast 2022-2027
      • Exhibit 109: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 110: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 111: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 112: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 113: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 114: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 116: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 117: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 118: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 119: Matrix on vendor position and classification
            • 12.3 Amgen Inc.
              • Exhibit 120: Amgen Inc. - Overview
              • Exhibit 121: Amgen Inc. - Product / Service
              • Exhibit 122: Amgen Inc. - Key offerings
            • 12.4 Baxter International Inc.
              • Exhibit 123: Baxter International Inc. - Overview
              • Exhibit 124: Baxter International Inc. - Business segments
              • Exhibit 125: Baxter International Inc. - Key news
              • Exhibit 126: Baxter International Inc. - Key offerings
              • Exhibit 127: Baxter International Inc. - Segment focus
            • 12.5 Bayer AG
              • Exhibit 128: Bayer AG - Overview
              • Exhibit 129: Bayer AG - Business segments
              • Exhibit 130: Bayer AG - Key news
              • Exhibit 131: Bayer AG - Key offerings
              • Exhibit 132: Bayer AG - Segment focus
            • 12.6 Daiichi Sankyo Co. Ltd.
              • Exhibit 133: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 134: Daiichi Sankyo Co. Ltd. - Business segments
              • Exhibit 135: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 136: Daiichi Sankyo Co. Ltd. - Key offerings
              • Exhibit 137: Daiichi Sankyo Co. Ltd. - Segment focus
            • 12.7 F. Hoffmann La Roche Ltd.
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 139: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 140: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 141: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 142: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.8 GlaxoSmithKline Plc
              • Exhibit 143: GlaxoSmithKline Plc - Overview
              • Exhibit 144: GlaxoSmithKline Plc - Business segments
              • Exhibit 145: GlaxoSmithKline Plc - Key offerings
              • Exhibit 146: GlaxoSmithKline Plc - Segment focus
            • 12.9 Heron Therapeutics Inc.
              • Exhibit 147: Heron Therapeutics Inc. - Overview
              • Exhibit 148: Heron Therapeutics Inc. - Product / Service
              • Exhibit 149: Heron Therapeutics Inc. - Key news
              • Exhibit 150: Heron Therapeutics Inc. - Key offerings
            • 12.10 Johnson and Johnson
              • Exhibit 151: Johnson and Johnson - Overview
              • Exhibit 152: Johnson and Johnson - Business segments
              • Exhibit 153: Johnson and Johnson - Key news
              • Exhibit 154: Johnson and Johnson - Key offerings
              • Exhibit 155: Johnson and Johnson - Segment focus
            • 12.11 Kyowa Kirin Co. Ltd.
              • Exhibit 156: Kyowa Kirin Co. Ltd. - Overview
              • Exhibit 157: Kyowa Kirin Co. Ltd. - Product / Service
              • Exhibit 158: Kyowa Kirin Co. Ltd. - Key offerings
            • 12.12 Merck and Co. Inc.
              • Exhibit 159: Merck and Co. Inc. - Overview
              • Exhibit 160: Merck and Co. Inc. - Business segments
              • Exhibit 161: Merck and Co. Inc. - Key news
              • Exhibit 162: Merck and Co. Inc. - Key offerings
              • Exhibit 163: Merck and Co. Inc. - Segment focus
            • 12.13 Novartis AG
              • Exhibit 164: Novartis AG - Overview
              • Exhibit 165: Novartis AG - Business segments
              • Exhibit 166: Novartis AG - Key offerings
              • Exhibit 167: Novartis AG - Segment focus
            • 12.14 Purdue Pharma LP
              • Exhibit 168: Purdue Pharma LP - Overview
              • Exhibit 169: Purdue Pharma LP - Product / Service
              • Exhibit 170: Purdue Pharma LP - Key offerings
            • 12.15 Sanofi SA
              • Exhibit 171: Sanofi SA - Overview
              • Exhibit 172: Sanofi SA - Business segments
              • Exhibit 173: Sanofi SA - Key news
              • Exhibit 174: Sanofi SA - Key offerings
              • Exhibit 175: Sanofi SA - Segment focus
            • 12.16 Sun Pharmaceutical Industries Ltd.
              • Exhibit 176: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 177: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 178: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.17 Teva Pharmaceutical Industries Ltd.
              • Exhibit 179: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 180: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 181: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 182: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 183: Teva Pharmaceutical Industries Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 184: Inclusions checklist
                • Exhibit 185: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 186: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 187: Research methodology
                • Exhibit 188: Validation techniques employed for market sizing
                • Exhibit 189: Information sources
              • 13.5 List of abbreviations
                • Exhibit 190: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              cancer supportive care market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis